$PFSA

Profusa, Inc. (PFSA): Entry into a Material Definitive Agreement

Profusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Senior Secured Convertible Promissory Note On September 16, 2026, Profusa, Inc., a Delaware corporation (the “Company”), completed an additional closing under that certain Securities Purchase Agreement, dated as of February 11

Original reporting
Published Sep 16, 2026, 10:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 10:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$PFSA
Neutral
medium confidence
Mentioned
$PFSA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PFSANeutralLow
01

Why it matters

The financing provides immediate capital but introduces conversion risk and a mandatory prepayment clause, which may affect share price and investor sentiment.

02

Market read

Primary micro‑cap financing news; limited broader market impact.

03

What to watch

Potential future conversion if share price rises above $4.28 could increase dilution beyond current expectations.

Relevance 6/10Novelty 6/10Timing: on filing day September 16, 2026

Background

Profusa Inc. (PFSA) filed a Form 8‑K detailing a senior secured convertible promissory note issuance as part of its securities purchase agreement with Ascent Partners Fund.

Company-level read

Ticker impact

$PFSANeutralMedium confidence
Context

Profusa filed an 8‑K reporting issuance of a $384,615 senior secured convertible promissory note with 7% interest and a $4.28 conversion price.

Expected impact

Potential slight downside as market prices in the new obligation; upside if conversion terms are viewed favorably.

Evidence & confidence

Small raise for a micro‑cap; impact limited to liquidity and dilution considerations.

Market effects

Minimal effect on the broader biotech/diagnostics sector; similar firms may see comparable financing trends.

Limited to U.S. micro‑cap market; no broader regional impact.

Low global relevance; isolated to Profusa shareholders.

Counterpoint

The note’s conversion floor and mandatory prepayment could constrain upside, suggesting a cautious stance.

Key entities

  • Profusa, Inc.

    Issuer of the convertible note.

  • Ascent Partners Fund LLC

    Purchaser and collateral agent for the note.

Related articles

$PFSALow

Profusa, Inc. (PFSA): Results of Operations and Financial Condition

Profusa, Inc. (PFSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of w

$FDMTMed

Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.

$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

$PFSAMedAI 8/10

PFSA Stock Falls 19% Amid Diagnostics Acquisition News

Profusa (PFSA) said it signed a non-binding term sheet to acquire a privately held commercial diagnostics and toxicology testing company. The target estimates 2025 net revenues of about $111 million. Profusa would issue shares equal to 19.99% plus non-voting convertible preferred stock, subject to approval, and expects about $7 million financing via convertible notes. PFSA shares fell sharply after the news.